Trevor is a Venture Partner in the Medicxi investment team. He co-founded Xo1 Ltd (acquired by Janssen in 2015), Apcintex Ltd and SuperX Ltd. He is the Chief Medical Officer for Rebalance Ltd and Human Antibody Factory.
Prior to joining Medicxi, he was a clinician at Cambridge University Hospitals where he was also Director of Investigative Sciences. His main research interests were in personalised risk profiling, developed from studying the gene-environment interaction leading to thrombosis, and the molecular basis of blood coagulation, which led to his interest in drug discovery and development. He has published more than 300 clinical and scientific papers and led the production of many national and international clinical guidelines.
Trevor served as President of the British Society for Haematology, President of the British Society for Haemostasis and Thrombosis and was a Founder of the European Congress for Thrombosis and Haemostasis.
He qualified in Medicine from Manchester University and was awarded his PhD from the University of Birmingham. He is a Fellow of the Royal College of Physicians and a Fellow of the Royal College of Pathologists.